Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
about
miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600ESystemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature.Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.Order Matters: The Order of Somatic Mutations Influences Cancer Evolution.Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy.Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword?Editorial: US Cancer Statistics of Survival: Achievements, Challenges, and Future Directions.Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer.Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer.Novel targeted therapies and immunotherapy for advanced thyroid cancers.The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.Metabolic Reprogramming in Thyroid Carcinoma.Activity of roniciclib in medullary thyroid cancer.Circulating tumor DNA (ctDNA) in the era of personalized cancer therapyMeta-analysis of microarray datasets identify several chromosome segregation-related cancer/testis genes potentially contributing to anaplastic thyroid carcinoma
P2860
Q37035505-E75684EC-8DBC-4DA1-853A-14F53A73141CQ37687310-38FD0EC4-E160-46F5-9B57-54EAE8C51552Q37746163-D7877B57-D280-44B7-AD1B-B00EAD9CB7D3Q38824017-5E3F915C-9E65-42F8-939D-4C76A25DEC91Q38865611-8894C9B8-B438-47F9-91FB-EA07B3AF7737Q38883187-48410661-FDE6-4115-AA22-ADA2A7F70A6BQ38972528-B8E97FDC-715D-4515-A00E-B6F0D3D4959EQ38973621-51D75667-F22F-4648-87C6-F9BC60C90FE3Q39092636-8CFE7738-E19C-4430-B744-B98CC5C5D428Q46073511-E1CD989A-A222-4993-AA27-8DAB32C14F56Q47647111-0003A391-9193-446D-8C5A-8E2FFC119307Q47926517-F57FC695-17D9-49CB-B826-D59833155A1FQ48232606-FB546CC2-C699-441E-AC06-17224D8DF3B8Q48274471-39BEE8D7-D199-479E-B8D9-1AADCB7FB0CFQ49887965-C3A5664B-15CD-49B3-B4FC-0E0DC11A872AQ50085302-46297FA9-5EF2-479B-994C-ECBB6A9554B9Q53697345-B0B485D3-AB8A-4BA4-A937-1375739D0000Q55363491-DFC5D8AE-DCF2-41EA-A411-B949CF79B23FQ57147396-D3B6B49A-C1CB-45E7-963C-E02FAD8EC264Q58569105-6BF05D38-8AED-4F9B-90EE-8E49111E1EA5
P2860
Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
@en
type
label
Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
@en
prefLabel
Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
@en
P2860
P1476
Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
@en
P2093
Keith C Bible
Mabel Ryder
P2860
P2888
P304
P356
10.1038/NRCLINONC.2016.19
P407
P577
2016-03-01T00:00:00Z
P6179
1053128534